Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. As altered methylation often activates or silences genes, changes in the epigenome can affect gene expression and the rate of cancer progression.
Next-generation sequencing (NGS) and microarray technologies can detect altered methylation patterns and other epigenetic changes in cancer. Illumina works with cancer epigenetics experts to ensure its NGS and array solutions meet the field's rapidly evolving needs.
Aberrant methylation is a common epigenetic alteration in cancer. NGS allows researchers to identify and compare methylation across the genome in cancer vs. normal cells, and gain insight into methylation patterns at a single nucleotide level.Learn More About Methylation Sequencing
Methylation microarrays enable epigenome-wide association studies that can analyze multiple cancer samples in parallel. Arrays quantitatively interrogate methylation sites across the genome, providing researchers with insight into the regulation of cancer-related genes and pathways.Learn More About Methylation Arrays
Se Hoon Kim, MD, PhD explains how combining NGS panels with methylation microarrays can deliver value in tumor characterization for clinical research.Read Interview
An NGS method that maps open chromatin regions helps researchers gain a better understanding of the epigenome and its impact on cancer and autoimmune diseases.Read Interview
Researchers identify genomic alterations associated with a deadly oral cancer, including somatic and germline variants as well as changes in promoter methylation and transcription.Read Interview
Altered transcription factor binding is another common epigenetic change linked to cancer. Chromatin immunoprecipitation sequencing (ChIP-Seq) can provide a genome-wide snapshot of DNA-associated protein activity in cancer vs. normal cells.
The method offers hypothesis-free insights into the regulation of gene expression. Deep sequencing enables detection of lower-abundance protein-DNA interactions often observed with transcription factors.Learn More About ChIP-Seq
Dr. Gelareh Zadeh and Dr. Farshad Nassiri highlight transformative research using DNA methylation technology and methylome-based predictors to understand meningioma recurrence risk.View Webinar
Dr. Matija Snuderl discusses his team's research into the use of machine learning and epigenetic signatures to improve the accuracy of solid tumor classifications, especially for brain tumors and sarcomas.View Webinar
In episode 21 of the Illumina Genomics Podcast, we discuss the epigenetics and epigenomics of cancer with Dr. Peter Scacheri, Professor of Genetics and Genome Sciences at Case Western Reserve University in Cleveland, Ohio.Listen Now
The assay for transposase-accessible chromatin with sequencing (ATAC-Seq) involves sequencing regions of open chromatin across the genome. This information can provide insights into how chromatin packaging affects cancer gene expression.This method does not require prior knowledge of regulatory elements, making it a powerful epigenetic discovery tool.Learn More About ATAC-Seq
Professor Andreas von Deimling from the University of Heidelberg presents results using methylation arrays and NGS in neuro-oncology research. He shares his vision on how these analyses could be applied to develop brain tumor diagnostics in the future.View Video
A study of pre-diagnostic blood samples identifies epigenome-wide hypomethylation changes that may predict breast cancer risk.Read Publication
This study identifies epigenetic patterns associated with T-cell exhaustion, and suggests potential future approaches for overcoming exhaustion in chimeric antigen receptor (CAR) T-cell immunotherapies.Read Publication
A review of recent epigenetic discoveries in prostate cancer, highlighting their potential as biomarkers for diagnosis, segmentation, and monitoring.Read Publication